|By Business Wire||
|June 16, 2014 09:06 AM EDT||
Advanced Biological Laboratories (ABL), S.A., announces the signing of a licensing and collaboration agreement with Tute Genomics. ABL is also pleased to announce the commercial launch of OncoChek™ for managing and analysing genomics data in the field of oncology.
OncoChek™ is derived from the clinically validated, professional software package, DeepChek® for Next-Generation Sequencing (NGS) data analysis. OncoChek™, in collaboration with Tute Genomics, now has the requisite capabilities to drive advances in personalized medicine and healthcare, as oncology is starting to benefit from NGS data and the interpretations of drug sensitivities provided by that data.
“Tute Genomics’ platform is one of the leading genome analysis software available currently on the market, allowing researchers to rapidly discover novel disease genes and identify predictive biomarkers. It can also help interpret NGS data for clinical reporting”, says Dr Chalom Sayada, CEO of ABL. “With the continuous pipeline of new features appearing in the Tute Genomics platform including a broad range of updated annotation content, the capability to rapidly analyse whole genomes or whole exomes, there is a natural fit with our own OncoChek™ platform”.
“We see Tute Genomics’ platform to be an extremely valuable addition to the features available from publicly available genomic databases which are already part of OncoChek™. Thus it is fully complementary with the DNA sequence analysis and clinical genotyping reporting cancer specific, that ABL has already provided to its customers and partners”, adds Dr Sayada. “The addition of the Tute Genomics platform combined with our know-how in clinical reporting on the medically relevant mutants and their associated drug response should ease the work of laboratories and researchers by providing them with validated and professional tools that should bring new results compared with currently available products”.
The agreement enables ABL to sell Tute Genomics services in Europe, Africa, Middle East and some countries in Asia where ABL has already a presence on its own or through local partnerships.
“We are thrilled to have ABL represent Tute in Europe and other major international territories. With this strategic partnership in place, we expect to achieve even greater sales growth going forward through broader distribution of our genome interpretation platform,” says Tute Genomics CEO, Reid Robison, MD MBA.
About Tute Genomics
Tute Genomics is a Utah-based company developing innovative cloud-based solutions to accelerate genetic discovery and enable precision medicine. Tute developed a clinical genome interpretation platform that assists researchers in identifying disease genes and biomarkers, and assists clinicians/labs in performing genetic diagnosis. Given sequencing data on a genome or a panel of genes, Tute can return over 125 annotations on variants and genes, perform family-based, case/control or tumor sample analyses to identify causal disease genes, and generate clinical reports for clinicians to focus on clinically relevant and actionable findings. Tute is built on the expertise that developed ANNOVAR, the most widely used genome annotation & interpretation technology with over 700 scientific publications. To learn more please visit www.tutegenomics.com.
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management tools, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and OncoChek™, which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL's products received CE-marking for IVD use. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, for sequencing, clinical genotyping, and drug resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high-throughput Next Generation Sequencing data. More at www.ablsa.com.
All trademarks used or mentioned in this release are protected by law.